Disclosed are novel compounds for CNS neurotransmitter systems, especially for the neurotransmitter serotonin, which have formula (I), where each of U, V, W, X, Y and Z is independently selected from the group consisting of hydrogen; halogen; C1-C4 alkyl; C1-C4 alkyl substituted with one ore more moieties selected from halogen atoms and hydroxy groups; C1-C4 alkoxy; C1-C4 alkoxy substituted with one ore more moieties selected from halogen atoms and hydroxy groups; C1-C6 heterocycles; C1-C4 thioalkyl; NR3R4; -R5-A-R6; and -A-R7; CN; SO2R8; -NHCONH2; and C(O)NR3R4; each of R1, R2, R3 and R4 is independently selected from the group consisting of hydrogen and C1-C4 alkyl; each of R5 and R6 is independently a C1-C6 alkyl; R7 is selected from the group consisting of H, C1-C6 alkyl, C1-C6 heterocycles or -A-R5; R8 is selected from the group consisting of C1-C4 alkyl and NR3R4; A is selected from the group consisting of S, N and O; provided that at least one of U, V, W, X, Y and Z is a halogen atom; and pharmaceutically acceptable salts thereof.
SEROTININ REUPTAKE INHIBITORS FOR S.P.E.C.T IMAGING